You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Suppliers and packagers for generic pharmaceutical drug: EXEMESTANE


✉ Email this page to a colleague

« Back to Dashboard


EXEMESTANE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Pfizer AROMASIN exemestane TABLET;ORAL 020753 NDA Pharmacia & Upjohn Company LLC 0009-7663-04 30 TABLET in 1 BOTTLE (0009-7663-04) 1999-10-21
Pfizer AROMASIN exemestane TABLET;ORAL 020753 NDA AUTHORIZED GENERIC Mylan Pharmaceuticals Inc. 59762-2858-1 30 TABLET, SUGAR COATED in 1 BOTTLE (59762-2858-1) 2011-04-01
Amneal Pharms EXEMESTANE exemestane TABLET;ORAL 206421 ANDA Amneal Pharmaceuticals LLC 65162-240-03 30 TABLET, FILM COATED in 1 BOTTLE (65162-240-03) 2018-12-29
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Exemestane

Last updated: July 28, 2025

Introduction

Exemestane, marketed under brand names such as Aromasin, is an aromatase inhibitor predominantly used in hormone receptor-positive breast cancer treatment. Its efficacy in reducing estrogen production has positioned it as a critical therapeutic agent, especially among postmenopausal women. As demand for exemestane continues to grow globally, understanding its primary suppliers, manufacturing landscape, and supply chain dynamics is essential for stakeholders ranging from pharmaceutical companies to healthcare providers. This report offers a comprehensive analysis of the key suppliers, manufacturing sources, and strategic considerations surrounding exemestane.


Manufacturing Landscape of Exemestane

Exemestane is a synthetic steroidal compound with a complex chemical synthesis process. Its production involves multiple steps, integrating advanced chemical synthesis techniques, stringent quality control, and compliance with regulatory standards such as Good Manufacturing Practice (GMP). Several pharmaceutical companies, both established players and emerging manufacturers, dominate the supply landscape.


Major Suppliers and Manufacturers

1. Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical is among the leading manufacturers of exemestane globally, supplying both branded and generic versions. The Indian-based firm leverages a robust R&D infrastructure and expansive manufacturing facilities to produce high-quality exemestane. Their products meet international regulatory standards, including USFDA and EMA approvals, which bolster their credibility across global markets[1].

2. Dr. Reddy’s Laboratories

Another prominent Indian pharmaceutical entity, Dr. Reddy’s, manufactures exemestane for both domestic and export markets. Their strategic focus on generics and biosimilars positions them well in the oncology segment. Their manufacturing plants maintain compliance with global quality standards, ensuring market acceptance[2].

3. Apotex Inc.

Canada's Apotex is known for producing an array of generic pharmaceuticals, including exemestane. Their emphasis on affordability and quality makes them a significant supplier for countries with price-sensitive healthcare markets. Apotex operates multiple manufacturing sites globally, ensuring supply chain resilience[3].

4. Zhejiang Hisun Pharmaceutical Co., Ltd.

China-based Zhejiang Hisun is expanding its portfolio to include high-margin oncology drugs like exemestane. Their adherence to GMP standards and participation in international regulatory approvals position them as a noteworthy supplier in Asian markets[4].

5. Hetero Labs Limited

Hetero, also based in India, manufactures a broad spectrum of generics. Their facilities are GMP-certified, and they target regulated markets, including the US and Europe, with high-quality exemestane formulations[5].

6. Other Notable Manufacturers

Additional companies such as Sandoz (Novartis), Mylan (now part of Viatris), and Aurobindo Pharma also produce exemestane for global markets. These companies have extensive distribution networks and manufacturing capabilities, increasing supply stability.


Supply Chain Dynamics and Market Factors

Regulatory Approvals

Manufacturers must secure approval from agencies such as the USFDA, EMA, PMDA (Japan), and others. These approvals influence manufacturing standards, capacity expansion, and export potential. For instance, Sun Pharma and Dr. Reddy’s have multiple approvals, facilitating broad market access.

Raw Material Sourcing

Exemestane synthesis requires high-purity intermediates, sourced globally. Disruptions in raw material supply, geopolitical factors, or regulatory barriers can impact production capacity.

Pricing and Market Competition

Generic competition has driven prices downward, compelling manufacturers to optimize production costs. Companies like Apotex and Aurobindo benefit from economies of scale, allowing them to sustain supply amidst competitive pricing.

Patents and Market Exclusivity

While the original patent for exemestane expired in multiple regions around 2015, some markets still hold regulatory exclusivities, influencing the entry of generics. This status shifts over time, impacting supplier landscape dynamics.


Emerging Trends in Exemestane Supply

1. Increased Production by Asian Manufacturers

India and China are becoming pivotal in extemestane supply, motivated by lower manufacturing costs and expanding export capacities. This expansion raises questions about regulatory compliance and quality assurance, which stakeholders must monitor.

2. Supply Chain Resilience and Diversification

Global supply chain disruptions, such as those caused by the COVID-19 pandemic, have bolstered efforts to diversify manufacturing sources. Companies are investing in regional manufacturing hubs to mitigate risks.

3. Regulatory Harmonization

Efforts toward regulatory harmonization, such as through ICH guidelines, streamline approval processes, enabling faster market access for new suppliers and improving supply security.


Quality and Regulatory Standards

Manufacturers of exemestane uphold rigorous manufacturing standards, including GMP and ISO certifications. Ensuring quality consistency is paramount, given the drug's critical role in oncology therapy, where efficacy and safety depend on pure and well-characterized compounds.


Key Considerations for Stakeholders

  • Supply Security: Buyers should prioritize manufacturers with validated capacity and regulatory approvals to ensure uninterrupted supply.
  • Quality Assurance: Ensuring compliance with international standards minimizes risks associated with substandard products.
  • Pricing Strategies: Competitive bidding and long-term supply agreements can facilitate cost-effective procurement.
  • Emerging Market Penetration: Indian and Chinese manufacturers expanding their footprint provide opportunities for localized sourcing in Asia and Africa.
  • Regulatory Developments: Staying abreast of patent expiries and regulatory changes enhances strategic sourcing decisions.

Key Takeaways

  • Leading suppliers include Sun Pharma, Dr. Reddy’s, Apotex, Zhejiang Hisun, and Hetero, among others, with manufacturing rooted predominantly in India, China, and North America.
  • Supply chain resilience is increasingly critical due to geopolitical and pandemic-related disruptions.
  • Regulatory approval ensures market access and maintains quality standards.
  • Asian manufacturers are expanding their global footprint, offering cost-effective alternatives.
  • Procurement strategies should focus on manufacturers with a proven compliance record and capacity to meet global demand.

FAQs

1. Who are the top global suppliers of exemestane?
The leading suppliers include Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Apotex, Zhejiang Hisun, and Hetero Labs, with manufacturing facilities across India, China, Canada, and North America.

2. What factors influence the supply stability of exemestane?
Supply stability depends on manufacturing capacity, raw material availability, regulatory approvals, global demand, and geopolitical stability.

3. How do regulatory standards impact exemestane manufacturing?
Compliance with GMP and other international standards ensures product safety and quality, facilitating market access and minimizing recall risks.

4. Are there regional differences in exemestane suppliers?
Yes. Indian and Chinese manufacturers dominate the Asian and emerging markets due to cost advantages, while North American and European companies focus on regulated markets like the US and EU.

5. What trends are shaping the future supply landscape of exemestane?
Increased Asian manufacturing capacity, emphasis on supply chain resilience, regulatory harmonization efforts, and technological innovations in synthesis are key trends influencing future supply.


References

[1] Sun Pharmaceutical Industries Ltd. — Corporate reports and approval documents.
[2] Dr. Reddy’s Laboratories. — Product approval and manufacturing info.
[3] Apotex Inc. — Global supply chain overview.
[4] Zhejiang Hisun Pharmaceutical Co., Ltd. — Market expansion and regulatory filings.
[5] Hetero Labs Limited. — GMP compliance and market strategy.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.